CollPlant Biotechnologies Ltd.
CLGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, CollPlant Biotechnologies Ltd. (CLGN) is listed under Biotechnology. Valued at $7.1M, CLGN is a micro-cap name in its sector. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Market Cap
$7.1M
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
-9.63
EPS (TTM)
$-9.03
EPS (Fwd)
$-0.39
ROE
-162.0%
ROA
-62.9%
Cash
$2.6M
Total Debt
$2.7M
Free CF
-$6.9M
52W Change
-83.4%
Annual Financials
Cash vs Debt
Where CLGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLGN finished 7.29% below its 150-day moving average ($3.84) and 36.54% below its 200-day moving average ($5.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLGN overbought or oversold?
At the October 20, 2026 close, CLGN's RSI(14) was 46.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CollPlant Biotechnologies Ltd. carries $2.7M in total debt against $2.6M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$6.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -162.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $299K (2022) to $2.4M (2025), reflecting a 693% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLGN.